Literature DB >> 31465186

Subclinical markers of atherosclerosis and cardiovascular risk factors in early arthritis.

Carla Andrea Gobbi1, Patricia Asbert, Paula Beatriz Alba, Jorge Resk, Gladys Dotto, Marcela Demarchi, Eduardo Cuvertino, Gustavo Alberto Pepe, Daniel Antonio Salica, Eduardo Horacio Albiero, Felipe Martínez.   

Abstract

Background: Mortality from cardiovascular disease (CVD) is increased in rheumatoid arthritis, not explained by traditional cardiovascular risk factors (CVRF), suggesting a role of inflammation. This process would occur early. The common sonographic markers of subclinical atherosclerosis (SA), are increased carotid intima-media thickness (cIMT) or the presence of carotid atherosclerotic plaque and they are closely related to CVD. Aims: To evaluate sonographic markers and cardiovascular risk factors in early Arthritis (EA).
Methods: A case control study of patients with EA, defined by 3 joints swollen with <1 year of evolution, served consecutively from January 2011 to may 2013, matched with healthy controls, by sex, age and cardiovascular risk factors (hypertension, diabetes mellitus, cardiovascular disease -IAM and ACV, dyslipidemia, family history of CVD) was conducted. We studied demographics data, cardiovascular risk factors, carotid ultrasound measuring increased cIMT or the presence of carotid atherosclerotic plaque in Common Carotid Artery (CCA) and Carotid Bulb (BC), laboratory test that included cholesterol, LDL, HDL, triglycerides in mg%, C-reactive protein (CRP), erythrocyte sedimentation rate (ESR ), anti citrullinated peptide (ACCP), rheumatoid factor (RF), antinuclear antibodies (ANA). EA activity was measured by DAS 28, considering high disease activity (HDA) 5.1; moderate (MDA) from 5.1 to 3.2; and low (LDA) <3.2. Statistics: test Mann-Whitney and chi-square were used, p <0.05 was significant.
Results: 25 women, 5 men, average age 43 years (DS 14.7) and 30 controls were included. The average DAS 28 was 4, 8 ± 1. 8; 47% had HDA, 33%MDA and 20%BDA. Both groups had similar values cIMT CCA (0, 57 ± 0.10 mm vs. 0.58 ± 0.15 mm, respectively, P = 0.82) and cIMT BC (0.18mm ± 0.67 vs 0.62 ± 0.15 mm respectively, P = 0.47). There were no carotid plaques. The median total cholesterol was 181,5 vs 183,5 (p = 0.35); triglycerides 99 vs 92,5 (p = 0.68); HDL 54,5 vs 52,5 (p = 0.921 and LDL 105 vs 110 (p = 0.27) in EA and controls respectively. The cIMT CCA and CB were not related to RF, ACCP, CRP, DAS 28 and smoking (NS). There was no difference in other cardiovascular risk factors Conclusions: Ultrasound evidence of atherosclerosis subclinical markers was not found in this study, suggesting that this process may occur after a year of diagnosis. Universidad Nacional de Córdoba

Entities:  

Keywords:  "medicine"; "rheumatology"; "cardiology"

Mesh:

Substances:

Year:  2019        PMID: 31465186     DOI: 10.31053/1853.0605.v76.n3.21610

Source DB:  PubMed          Journal:  Rev Fac Cien Med Univ Nac Cordoba        ISSN: 0014-6722


  3 in total

1.  Cardiovascular Magnetic Resonance Detects Inflammatory Cardiomyopathy in Symptomatic Patients with Inflammatory Joint Diseases and a Normal Routine Workup.

Authors:  George Markousis-Mavrogenis; Maria Bonou; Vasiliki Vartela; Genovefa Kolovou; Aliki Venetsanopoulou; Theodora Markatseli; Anastasia Skalkou; Zoi Tziortzioti; Paraskevi Voulgari; Sophie I Mavrogeni
Journal:  J Clin Med       Date:  2022-03-05       Impact factor: 4.241

2.  Assessment of Adipokines, CXCL16 Chemokine Levels in Patients With Rheumatoid Arthritis Combined With Metabolic Syndrome.

Authors:  Lyudmila Gennadyevna Turgunova; Anna Andreevna Shalygina; Janis Pavlovich Zalkalns; Dmitriy Anatolyevich Klyuyev; Lyudmila Leonidovna Akhmaltdinova; Raushan Sultanovna Dosmagambetova
Journal:  Clin Med Insights Arthritis Musculoskelet Disord       Date:  2021-02-05

3.  Diagnostic and Prognostic Significance of miR-675-3p in Patients With Atherosclerosis.

Authors:  Shuangquan Wang; Wei Shao; Yang Gao; Hongwei Zhao; Deyong Du
Journal:  Clin Appl Thromb Hemost       Date:  2021 Jan-Dec       Impact factor: 2.389

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.